Compare ACADIA Pharmaceuticals Inc. (ACAD) vs United Parcel Service Inc (UPS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs United Parcel Service Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while United Parcel Service Inc trades at $109.13 (market cap $95.17B). The key difference: United Parcel Service Inc is far larger — about 21.2× ACADIA Pharmaceuticals Inc.'s market cap, and United Parcel Service Inc pays a 5.86% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | UPS | |
|---|---|---|
Market Cap | $4.49B | $95.17B |
Sector | Health | Industrials |
52-Week High | $28.06 | $120.00 |
52-Week Low | $20.06 | $82.58 |
Enterprise Value | $3.69B | $118.03B |
Volume | — | 2,288,643 |
Dividend Yield | — | 5.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
UPS trades at $111.96, up 1.15% with a bullish technical signal. Recent earnings beat expectations (Q1 2026 EPS of $1.07 vs. $1.02 expected), though revenue declined to $88.66B in 2025. The company invests in healthcare logistics and AI to boost efficiency. Valuation ratios appear reasonable with P/E of 17.8 and P/S of 1.06. Analyst consensus is mixed with 42% buy ratings and a $111 price target.
Outlook: UPS faces revenue pressure but maintains solid profitability (ROE 33.41%). Strategic investments in temperature-controlled facilities and AI could drive growth. Risks include competitive threats and economic sensitivity. The stock offers stability with dividend income, but upside may be limited near the consensus target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
